197 related articles for article (PubMed ID: 35675429)
1. Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.
Wang G; Kumar A; Ding W; Korangath P; Bera T; Wei J; Pai P; Gabrielson K; Pastan I; Sukumar S
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2200200119. PubMed ID: 35675429
[TBL] [Abstract][Full Text] [Related]
2. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin.
Shinohara H; Fan D; Ozawa S; Yano S; Van Arsdell M; Viner JL; Beers R; Pastan I; Fidler IJ
Int J Oncol; 2000 Oct; 17(4):643-51. PubMed ID: 10995873
[TBL] [Abstract][Full Text] [Related]
3. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
Debinski W; Pastan I
Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
[TBL] [Abstract][Full Text] [Related]
4. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv).
Batra JK; Fitzgerald DJ; Chaudhary VK; Pastan I
Mol Cell Biol; 1991 Apr; 11(4):2200-5. PubMed ID: 2005905
[TBL] [Abstract][Full Text] [Related]
5. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Friedman PN; Chace DF; Trail PA; Siegall CB
J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
[TBL] [Abstract][Full Text] [Related]
8. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.
Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S
J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808
[TBL] [Abstract][Full Text] [Related]
9. The effects of transferrin receptor antibody, transferrin receptor antibody bound to Pseudomonas exotoxin and transforming growth factor-alpha bound to Pseudomonas exotoxin on human tenon's capsule fibroblast proliferation.
Smyth RJ; Kitada S; Lee DA
J Ocul Pharmacol; 1992; 8(1):83-90. PubMed ID: 1402298
[TBL] [Abstract][Full Text] [Related]
10. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.
Kreitman RJ; Chaudhary VK; Waldmann T; Willingham MC; FitzGerald DJ; Pastan I
Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8291-5. PubMed ID: 2236041
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
[TBL] [Abstract][Full Text] [Related]
12. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
13. Preclinical assessment of an anti-EpCAM immunotoxin: locoregional delivery provides a safer alternative to systemic administration.
Brown J; Rasamoelisolo M; Spearman M; Bosc D; Cizeau J; Entwistle J; MacDonald GC
Cancer Biother Radiopharm; 2009 Aug; 24(4):477-87. PubMed ID: 19694583
[TBL] [Abstract][Full Text] [Related]
14. Intraductal fulvestrant for therapy of ERα-positive ductal carcinoma in situ of the breast: a preclinical study.
Wang G; Chen C; Pai P; Korangath P; Sun S; Merino VF; Yuan J; Li S; Nie G; Stearns V; Sukumar S
Carcinogenesis; 2019 Jul; 40(7):903-913. PubMed ID: 31046118
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer.
FitzGerald DJ; Willingham MC; Pastan I
Proc Natl Acad Sci U S A; 1986 Sep; 83(17):6627-30. PubMed ID: 3018739
[TBL] [Abstract][Full Text] [Related]
16. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U
Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731
[TBL] [Abstract][Full Text] [Related]
17. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
[TBL] [Abstract][Full Text] [Related]
18. Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines.
Pirker R; FitzGerald DJ; Hamilton TC; Ozols RF; Willingham MC; Pastan I
Cancer Res; 1985 Feb; 45(2):751-7. PubMed ID: 2981613
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.
Bigner DD; Archer GE; McLendon RE; Friedman HS; Fuchs HE; Pai LH; Herndon JE; Pastan IH
Clin Cancer Res; 1995 Dec; 1(12):1545-55. PubMed ID: 9815955
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer.
Wolf P; Alt K; Wetterauer D; Bühler P; Gierschner D; Katzenwadel A; Wetterauer U; Elsässer-Beile U
J Immunother; 2010 Apr; 33(3):262-71. PubMed ID: 20445346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
